Valeant Pharmaceuticals International (VRX) Sets New 1-Year High at $25.00
Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)’s share price hit a new 52-week high on Friday . The stock traded as high as C$25.00 and last traded at C$22.68, with a volume of 2166709 shares changing hands. The stock had previously closed at C$21.52.
Several brokerages have commented on VRX. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a C$23.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. TD Securities raised shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price for the company in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Valeant Pharmaceuticals International presently has an average rating of “Hold” and an average target price of C$22.50.
In other news, Director Schutter Richard Urbain De bought 10,000 shares of the stock in a transaction on Friday, November 17th. The stock was purchased at an average price of C$14.33 per share, with a total value of C$143,300.00.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.